Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases

Malara, Natalia; Guzzi, Giusy; Mignogna, Chiara; Trunzo, Valentina; Camastra, Caterina; Torre, Attilio Della; Vito, Anna Di; Lavecchia, Annamaria; Gliozzi, Micaela; Ceccotti, C.; Volpentesta, Giorgio; Lavano, Angelo; Donato, Giuseppe; Mollace, Vincenzo

doi:10.1186/s12883-016-0652-x

Cited by 20 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the way, the features of a so specific molecular marker must be exploited, integrating its detection with the rapidly developing techniques for the study of CTCs and circulating tumor nucleic acids; that can be combined with minimal invasiveness of liquid biopsy. The UbcH10 overexpression could be investigated directly on CTCs by immunocytochemical approaches, as demonstrated for other biomarkers [66][67][68][69], or by searching for its transcript in cell free circulating RNA in biological fluids. As it has been shown by recent, encouraging data from a study carried out on the urine of subjects with breast cancer [70], the analysis of UBE2C transcript levels could become a sensitive marker that can be exploited in diagnostics.…”

Section: Discussionmentioning

confidence: 99%

UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy

Presta

Novellino

Donato

et al. 2020

IJMS

View full text Add to dashboard Cite

Malignant transformation is a multistep process in which several molecular entities become dysregulated and result in dysfunction in the regulation of cell proliferation. In past years, scientists have gradually dissected the pathways involved in the regulation of the cell cycle. The mitotic ubiquitin-conjugating enzymes UbcH10, has been extensively studied since its cloning and characterization and it has been identified as a constantly overexpressed factor in many types of cancer. In this paper, we have reviewed the literature about UbcH10 in human cancer, pointing out the association between its overexpression and exacerbation of cancer phenotype. Moreover, many recalled studied demonstrated how immunohistochemistry or RT-PCR analysis can distinguish normal tissues and benign lesions from malignant neoplasms. In other experimental studies, many of the consequences of UbcH10 overexpression, such as increased proliferation, metastasizing, cancer progression and resistance to anticancer drugs are reversed through gene silencing techniques. In recent years, many authors have defined UbcH10 evaluation in cancer patients as a useful tool for diagnosis and therapy. This opinion is shared by the authors who advertise how it would be useful to start using in clinical practice the notions acquired about this important moleculein the carcinogenesis of many human malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy

Presta

Novellino

Donato

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…As shown in a mouse model of HER2 + (Erb-B2 Receptor Tyrosine Kinase 2) breast cancer, a permissive effect is also attributed to TAMs for the entry into the bloodstream of circulating tumor cells (CTC) [ 132 ]. The presence of CTC in patients with glioblastoma is well documented ( Figure 4 ) and its detection may have a guiding role in diagnosis, prognosis, and therapy [ 135 , 136 ]. Interestingly, CTC from gliomas show features of epithelial-mesenchimal transition [ 137 ].…”

Section: Discussionmentioning

confidence: 99%

Role of Macrophages in Brain Tumor Growth and Progression

Guadagno

Presta

Maisano

et al. 2018

IJMS

View full text Add to dashboard Cite

The role of macrophages in the growth and the progression of tumors has been extensively studied in recent years. A large body of data demonstrates that macrophage polarization plays an essential role in the growth and progression of brain tumors, such as gliomas, meningiomas, and medulloblastomas. The brain neoplasm cells have the ability to influence the polarization state of the tumor associated macrophages. In turn, innate immunity cells have a decisive role through regulation of the acquired immune response, but also through humoral cross-talking with cancer cells in the tumor microenvironment. Neoangiogenesis, which is an essential element in glial tumor progression, is even regulated by the tumor associated macrophages, whose activity is linked to other factors, such as hypoxia. In addition, macrophages play a decisive role in establishing the entry into the bloodstream of cancer cells. As is well known, the latter phenomenon is also present in brain tumors, even if they only rarely metastasize. Looking ahead in the future, we can imagine that characterizing the relationships between tumor and tumor associated macrophage, as well as the study of circulating tumor cells, could give us useful tools in prognostic evaluation and therapy. More generally, the study of innate immunity in brain tumors can boost the development of new forms of immunotherapy.

show abstract

“…After 9 months, the patient presented with tumour recurrence, and 5 months later had succumbed to the disease. 90 Along with imaging results, CTC analysis proved to be relevant in monitoring the patient's intracranial lesion.…”

Section: Ctcs In Glioblastomamentioning

confidence: 98%

“…Also, by using cell viability and apoptosis assays, the authors analysed the resistance of CTCs to radiotherapy and chemotherapy with TMZ and concluded that CTCs are more resistant to treatments and to stress induced in the circulation than other tumour cells. Malara et al 90 reported a case of a 67-year-old patient presenting with an intracranial lesion that was subsequently confirmed to be GBM. The patient's blood was collected before surgery and 2 months post-operation, and CTCs were captured by using density-gradient centrifugation.…”

Section: Ctcs In Glioblastomamentioning

confidence: 99%

Circulating biomarkers in patients with glioblastoma

et al. 2019

View full text Add to dashboard Cite

Gliomas are the most common tumours of the central nervous system and the most aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival remains low. GBM diagnosis typically relies on imaging techniques and postoperative pathological diagnosis; however, both procedures have their inherent limitations. Imaging modalities cannot differentiate tumour progression from treatment-related changes that mimic progression, known as pseudoprogression, which might lead to misinterpretation of therapy response and delay clinical interventions. In addition to imaging limitations, tissue biopsies are invasive and most of the time cannot be performed over the course of treatment to evaluate 'real-time' tumour dynamics. In an attempt to address these limitations, liquid biopsies have been proposed in the field. Blood sampling is a minimally invasive procedure for a patient to endure and could provide tumoural information to guide therapy. Tumours shed tumoural content, such as circulating tumour cells, cell-free nucleic acids, proteins and extracellular vesicles, into the circulation, and these biomarkers are reported to cross the blood-brain barrier. The use of liquid biopsies is emerging in the field of GBM. In this review, we aim to summarise the current literature on circulating biomarkers, namely circulating tumour cells, circulating tumour DNA and extracellular vesicles as potential non-invasively sampled biomarkers to manage the treatment of patients with GBM.

show abstract

Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases

Cited by 20 publications

References 17 publications

UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy

UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy

Role of Macrophages in Brain Tumor Growth and Progression

Circulating biomarkers in patients with glioblastoma

Contact Info

Product

Resources

About